| scholarly article | Q13442814 |
| P50 | author | Gavin P. Robertson | Q55873679 |
| P2093 | author name string | Dhimant Desai | |
| Shantu Amin | |||
| Arun K Sharma | |||
| Subbarao V Madhunapantula | |||
| Arati Sharma | |||
| Sung Jin Huh | |||
| Paul Mosca | |||
| P2860 | cites work | Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates | Q24563653 |
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining | Q24682187 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| The protein kinase B/Akt signalling pathway in human malignancy | Q28645742 | ||
| Natural products as sources of new drugs over the last 25 years | Q29615119 | ||
| Inhibition of nuclear factor-kappaB DNA binding by organoselenocyanates through covalent modification of the p50 subunit | Q30835417 | ||
| Treatments for metastatic melanoma: synthesis of evidence from randomized trials | Q33301788 | ||
| Drug-resistance in human melanoma | Q34321923 | ||
| Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. | Q34330731 | ||
| Deregulated Akt3 activity promotes development of malignant melanoma | Q34355872 | ||
| Ten years of protein kinase B signalling: a hard Akt to follow | Q34432885 | ||
| STI571: a paradigm of new agents for cancer therapeutics | Q34482385 | ||
| Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. | Q35914374 | ||
| Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms | Q35914378 | ||
| Functional and therapeutic significance of Akt deregulation in malignant melanoma. | Q36178371 | ||
| Vegetable-derived isothiocyanates: anti-proliferative activity and mechanism of action | Q36379685 | ||
| Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds | Q36399294 | ||
| Drug discovery from natural products | Q36424053 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Melanoma biology and new targeted therapy | Q36742015 | ||
| Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis | Q36757554 | ||
| From traditional Chinese medicine to rational cancer therapy. | Q36888420 | ||
| Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma | Q37015632 | ||
| Is B-Raf a good therapeutic target for melanoma and other malignancies? | Q37048982 | ||
| Microtubule-stabilizing natural products as promising cancer therapeutics | Q37066030 | ||
| Selenium compounds and selenoproteins in cancer | Q37115535 | ||
| Emerging therapies for melanoma | Q37134426 | ||
| Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases | Q37421620 | ||
| Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials | Q38502534 | ||
| PBISe, a novel selenium-containing drug for the treatment of malignant melanoma | Q39981770 | ||
| A novel activation-induced suicidal degradation mechanism for Akt by selenium. | Q40032055 | ||
| PRAS40 deregulates apoptosis in malignant melanoma | Q40144591 | ||
| Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells | Q40426301 | ||
| PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells | Q40432054 | ||
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 | ||
| Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest | Q40579395 | ||
| Suppressing effects of dietary supplementation of the organoselenium 1,4-phenylenebis(methylene)selenocyanate and the Citrus antioxidant auraptene on lung metastasis of melanoma cells in mice | Q40754469 | ||
| Chemoprevention by isothiocyanates | Q40933059 | ||
| Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. | Q41859138 | ||
| A link between benzyl isothiocyanate-induced cell cycle arrest and apoptosis: involvement of mitogen-activated protein kinases in the Bcl-2 phosphorylation | Q44802895 | ||
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 | ||
| Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells | Q46966363 | ||
| Structure-activity relationships for inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone lung tumorigenesis by arylalkyl isothiocyanates in A/J mice. | Q53499435 | ||
| Serum selenium levels in patients with malignant melanoma | Q69368064 | ||
| Loss of PTEN promotes tumor development in malignant melanoma | Q73469277 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1674-1685 | |
| P577 | publication date | 2009-02-10 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Targeting Akt3 signaling in malignant melanoma using isoselenocyanates | |
| P478 | volume | 15 |
| Q36413704 | AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2. |
| Q39445926 | Akt and RhoA inhibition promotes anoikis of aggregated B16F10 melanoma cells. |
| Q39648084 | Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates |
| Q38127412 | Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics |
| Q99605575 | COL2A1 Is a Novel Biomarker of Melanoma Tumor Repopulating Cells |
| Q36769227 | Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges |
| Q84948297 | Chemoprevention of melanoma |
| Q26781652 | Current State of Animal (Mouse) Modeling in Melanoma Research |
| Q39418345 | Diphenyl diselenide protects cultured MCF-7 cells against tamoxifen-induced oxidative DNA damage |
| Q28390405 | Drug delivery nanoparticles in skin cancers |
| Q35628374 | Expression of the platelet-activating factor receptor enhances benzyl isothiocyanate-induced apoptosis in murine and human melanoma cells |
| Q36288650 | Flotillin-2 promotes metastasis of nasopharyngeal carcinoma by activating NF-κB and PI3K/Akt3 signaling pathways |
| Q36563659 | Genetics of melanoma |
| Q58895043 | Identification and Distribution of Selenium-Containing Glucosinolate Analogues in Tissues of Three Brassicaceae Species |
| Q36750123 | Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma |
| Q64273467 | Identification of a Novel Quinoxaline-Isoselenourea Targeting the STAT3 Pathway as a Potential Melanoma Therapeutic |
| Q33569998 | Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma |
| Q38639775 | Mechanisms of Selenium Enrichment and Measurement in Brassicaceous Vegetables, and Their Application to Human Health |
| Q36384802 | Melanoma Prevention Using Topical PBISe |
| Q35535167 | Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4. |
| Q37262390 | MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma |
| Q33567626 | Mining mammalian transcript data for functional long non-coding RNAs |
| Q35225907 | Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. |
| Q38724921 | Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. |
| Q33973521 | Novel library of selenocompounds as kinase modulators. |
| Q38907413 | Patient-derived tumor xenograft models for melanoma drug discovery |
| Q36345357 | Phenylalkyl isoselenocyanates vs phenylalkyl isothiocyanates: Thiol reactivity and its implications |
| Q35523031 | Phenylbutyl isoselenocyanate modulates phase I and II enzymes and inhibits 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced DNA adducts in mice |
| Q38077547 | Post SELECT: Selenium on Trial |
| Q33907135 | Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. |
| Q28482143 | Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death |
| Q82445737 | Reactions of nitroxides. Part X: Antifungal activity of selected sulfur and selenium derivatives of 2,2,6,6-tetramethylpiperidine |
| Q39336516 | Selenium-containing histone deacetylase inhibitors for melanoma management |
| Q36536476 | Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma |
| Q43240660 | Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells |
| Q35606342 | Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway |
| Q35136450 | Targeting multiple key signaling pathways in melanoma using leelamine. |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q35091427 | The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. |
| Q34649075 | The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer |
| Q35911227 | The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. |
| Q91975278 | The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia |
| Q37506648 | The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma |
| Q64903636 | The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents. |
| Q35176448 | The T-box transcription factor, TBX3, is a key substrate of AKT3 in melanomagenesis |
| Q24631438 | Therapeutic Implications of Targeting AKT Signaling in Melanoma |
| Q36973754 | miR-29 targets Akt3 to reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle development. |
Search more.